David Epstein Sells 370 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $43.40, for a total transaction of $16,058.00. Following the completion of the sale, the director owned 31,094 shares of the company’s stock, valued at approximately $1,349,479.60. This trade represents a 1.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

Shares of TEM stock opened at $46.12 on Friday. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32. The business’s fifty day simple moving average is $51.29 and its 200-day simple moving average is $51.95. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market cap of $8.28 billion, a PE ratio of -32.03 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter last year, the firm earned ($0.22) EPS. The business’s quarterly revenue was up 21.6% on a year-over-year basis. Analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares during the period. ARK Investment Management LLC increased its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after buying an additional 381,816 shares during the period. GC Wealth Management RIA LLC acquired a new position in Tempus AI in the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. raised its position in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TEM shares. Guggenheim boosted their price target on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday. Finally, Jefferies Financial Group assumed coverage on shares of Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $64.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.